
X linked Adrenoleukodystrophy - Pipeline Insight, 2025
Description
DelveInsight’s, “X linked Adrenoleukodystrophy- Pipeline Insight, 2025,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in X linked Adrenoleukodystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
X linked Adrenoleukodystrophy: Overview
X linked adrenoleukodystrophy (X-ALD) is a genetic disease that affects the nervous system and the adrenal glands (small glands located on top of each kidney). People with this disease often have progressive loss of the fatty covering (myelin) that surrounds the nerves in the brain and spinal cord. They may also have a shortage of certain hormones that is caused by damage to the outer layer of the adrenal glands (adrenal cortex). This is called adrenocortical insufficiency, or Addison disease. There are three forms of X-ALD: a childhood cerebral form, an adrenomyeloneuropathy (AMN) type, and an adrenal-insufficiency-only-type. The disease primarily affects males. X-ALD is caused by a variation (mutation) in the ABCD1 gene and it is inherited in an X-linked. manner. Diagnosis of the disease is based on testing the levels of a molecule called very long-chain fatty acids (VLCFA). The diagnosis can be confirmed with genetic testing. There is still no cure for X-ALD, but taking special oils such as Lorenzo’s oil can lower the blood levels of VLCFA. Bone marrow transplantation may be an option for boys who have evidence of brain involvement on MRI, but do not yet have obvious symptoms of the disease with a normal neurological exam. With an estimated birth incidence of 1 in 17,000 newborns (male and female), X-ALD is the most common peroxisomal disorder. It occurs in all regions of the world. Now that newborn screening has become technically feasible and may be implemented in some parts of the world. The treatment for X-linked adrenoleukodystrophy (X-ALD) depends on the signs and symptoms present in each person. It is important to remember that the exact signs and symptoms of a person with X-ALD cannot be predicted by the signs and symptoms of other members of the family. Therefore, the long-term outlook for individuals who have X-ALD within the same family can be very different. As in many X-linked diseases, it was assumed that female carriers remain asymptomatic. An increasing number of symptomatic heterozygous women are identified as the first member of their family to be affected by X-ALD. A diagnosis of X-ALD must be followed by extended family screening together with a geneticist.
""X linked Adrenoleukodystrophy- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the X linked Adrenoleukodystrophy pipeline landscape is provided which includes the disease overview and X linked Adrenoleukodystrophy treatment guidelines. The assessment part of the report embraces, in depth X linked Adrenoleukodystrophy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, X linked Adrenoleukodystrophy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the X linked Adrenoleukodystrophy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
X linked Adrenoleukodystrophy Emerging Drugs
Further product details are provided in the report……..
X linked Adrenoleukodystrophy: Therapeutic Assessment
This segment of the report provides insights about the different X linked Adrenoleukodystrophy drugs segregated based on following parameters that define the scope of the report, such as:
X linked Adrenoleukodystrophy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses X linked Adrenoleukodystrophy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging X linked Adrenoleukodystrophy drugs.
X linked Adrenoleukodystrophy Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
X linked Adrenoleukodystrophy: Overview
X linked adrenoleukodystrophy (X-ALD) is a genetic disease that affects the nervous system and the adrenal glands (small glands located on top of each kidney). People with this disease often have progressive loss of the fatty covering (myelin) that surrounds the nerves in the brain and spinal cord. They may also have a shortage of certain hormones that is caused by damage to the outer layer of the adrenal glands (adrenal cortex). This is called adrenocortical insufficiency, or Addison disease. There are three forms of X-ALD: a childhood cerebral form, an adrenomyeloneuropathy (AMN) type, and an adrenal-insufficiency-only-type. The disease primarily affects males. X-ALD is caused by a variation (mutation) in the ABCD1 gene and it is inherited in an X-linked. manner. Diagnosis of the disease is based on testing the levels of a molecule called very long-chain fatty acids (VLCFA). The diagnosis can be confirmed with genetic testing. There is still no cure for X-ALD, but taking special oils such as Lorenzo’s oil can lower the blood levels of VLCFA. Bone marrow transplantation may be an option for boys who have evidence of brain involvement on MRI, but do not yet have obvious symptoms of the disease with a normal neurological exam. With an estimated birth incidence of 1 in 17,000 newborns (male and female), X-ALD is the most common peroxisomal disorder. It occurs in all regions of the world. Now that newborn screening has become technically feasible and may be implemented in some parts of the world. The treatment for X-linked adrenoleukodystrophy (X-ALD) depends on the signs and symptoms present in each person. It is important to remember that the exact signs and symptoms of a person with X-ALD cannot be predicted by the signs and symptoms of other members of the family. Therefore, the long-term outlook for individuals who have X-ALD within the same family can be very different. As in many X-linked diseases, it was assumed that female carriers remain asymptomatic. An increasing number of symptomatic heterozygous women are identified as the first member of their family to be affected by X-ALD. A diagnosis of X-ALD must be followed by extended family screening together with a geneticist.
""X linked Adrenoleukodystrophy- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the X linked Adrenoleukodystrophy pipeline landscape is provided which includes the disease overview and X linked Adrenoleukodystrophy treatment guidelines. The assessment part of the report embraces, in depth X linked Adrenoleukodystrophy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, X linked Adrenoleukodystrophy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence X linked Adrenoleukodystrophy R&D. The therapies under development are focused on novel approaches to treat/improve X linked Adrenoleukodystrophy.
This segment of the X linked Adrenoleukodystrophy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
X linked Adrenoleukodystrophy Emerging Drugs
- Leriglitazone : Minoryx Therapeutics
- PXL770: Poxel
- PLX065 : Poxel
- OP101 : Orpheris
Further product details are provided in the report……..
X linked Adrenoleukodystrophy: Therapeutic Assessment
This segment of the report provides insights about the different X linked Adrenoleukodystrophy drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in X linked Adrenoleukodystrophy
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
X linked Adrenoleukodystrophy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses X linked Adrenoleukodystrophy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging X linked Adrenoleukodystrophy drugs.
X linked Adrenoleukodystrophy Report Insights
- X linked Adrenoleukodystrophy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing X linked Adrenoleukodystrophy drugs?
- How many X linked Adrenoleukodystrophy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of X linked Adrenoleukodystrophy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the X linked Adrenoleukodystrophy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for X linked Adrenoleukodystrophy and their status?
- What are the key designations that have been granted to the emerging drugs?
- Minoryx Therapeutics
- Viking Therapeutics
- Poxel
- Orpheris
- Applied Genetic Technologies Corporation
- NEURALGENE
- PXL770
- PXL065
- OP101
- Leriglitazone
- PRCN 323
Table of Contents
40 Pages
- Introduction
- Executive Summary
- X linked Adrenoleukodystrophy: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- X linked Adrenoleukodystrophy– DelveInsight’s Analytical Perspective
- Late Stage Products (PhaseII/ III)
- Comparative Analysis
- Leriglitazone : Minoryx Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- PXL770: Poxel
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- OP101 : Orpheris
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- X linked Adrenoleukodystrophy Key Companies
- X linked Adrenoleukodystrophy Key Products
- X linked Adrenoleukodystrophy- Unmet Needs
- X linked Adrenoleukodystrophy- Market Drivers and Barriers
- X linked Adrenoleukodystrophy- Future Perspectives and Conclusion
- X linked Adrenoleukodystrophy Analyst Views
- X linked Adrenoleukodystrophy Key Companies
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.